ISMRC 2023 Final Programme

We strive to change lives through earlier detection and smarter answers across the CANCER CONTINUUM Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.  From hereditary cancer testing and earlier cancer screening to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests, that enables the delivery of personalized care to support patients before, during and after diagnosis. OUR PIPELINE Building on the success of the Cologuard ® and the Oncotype ® tests, Exact Sciences is investing in its product pipeline across the cancer continuum. This includes a multi-cancer early detection (MCED) blood test in development that has the potential to make routine screening for multiple types of cancer a reality. We are also developing solutions for molecular residual disease (MRD) testing that may provide a powerful indicator of long-term outcomes and help discover cancer recurrence earlier. EXS14017_0323_EN_INT_ISMRD 2023 flyer Date of preparation: March 2023 Cologuard, and Exact Sciences are registered trademarks of Exact Sciences Corporation. Oncotype DX is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences International GmbH Lindenstrasse 2, 6340 Baar, Switzerland © 2023 Exact Sciences Corporation. All rights reserved. For more information on Exact Sciences, please visit our website www.exactsciences.com or scan the QR code below. Pipeline tests are not available for commercial use. Availability of commercial tests outside of the US varies by country. Hereditary Cancer Screening Prognosis/Therapy Guidance Recurrence Monitoring Therapy Selection